Avast! What matters not to the outcome of a surgeon's blade in NSCLC, ye scurvy dogs?
2023-09-14
Arr, me hearties! The study AEGEAN be one of the earliest explorations of immune checkpoint inhibitors in the perioperative realm, showin' a jolly improvement in EFS and pCR! But worry ye not, for it had nay impact on the outcome of surgeries. Yo ho ho!
Arr, me hearties! Avast ye landlubbers! Listen up, me mateys! AEGEAN be a study o' immune checkpoint inhibitors, aye, in the perioperative settings. But let me tell ye, this study be quite a treasure to behold! It be showin' improved EFS and pCR, but fear not, it be havin' no effect on surgical outcomes. Arr, ye heard that right, me hearties!Now, ye might be wonderin', what be these immune checkpoint inhibitors? Well, me mateys, they be a fancy weapon against cancer. They be helpin' the body's own immune system fight against those scurvy cancer cells. And AEGEAN be one o' the first studies to look at how these inhibitors work in the perioperative settings.
But let's get to the real treasure, me hearties! AEGEAN be showin' improved EFS and pCR. EFS, that be "event-free survival," meanin' the time a patient be livin' without the cancer comin' back or any other events happenin'. And pCR, that be "pathological complete response," meanin' there be no evidence o' cancer left after treatment. Arr, that be some good news, indeed!
Now, ye might be worryin' about the surgical outcomes, but fear not, me mateys! AEGEAN be showin' no effect on 'em! So, ye can be restin' easy, knowin' that these immune checkpoint inhibitors be makin' a difference without messin' with the surgery.
So there ye have it, me hearties! AEGEAN be a study worth celebratin'! It be showin' improved EFS and pCR, without affectin' the surgical outcomes. It be a step forward in the fight against cancer, and a treasure worth cherishin'. Now, let's raise our mugs, give a cheer, and toast to the success of AEGEAN! Yo ho ho!